Trials / Completed
CompletedNCT03611491
Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds
A Prospective, Open Label, Multicenter, Post Market Study Evaluating Princess® FILLER Lidocaine for the Correction of Nasolabial Folds
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Croma-Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® FILLER Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator
Detailed description
A prospective, open label, multicenter, post-market investigation. Following informed consent and screening, eligible subjects with moderate to severe nasolabial folds were treated with Princess® FILLER Lidocaine, and were to return for follow-up assessments 2, 4, 24 and 36 weeks after the initial treatment. A Touch-up treatment may be done at Week 2 after initial treatment, if deemed appropriate by the investigator. The performance of the investigational device evaluated by the investigator by assessing severity of nasolabial folds using the Nasolabial Folds Severity Rating Scale (NLF-SRS) (4, 24 and 36 weeks after the initial treatment and in comparison to Day 0) and global aesthetic improvement (4, 24 and 36 weeks after the initial treatment). The subject evaluated pain intensity associated with the treatment (at Day 0 and at Week 2 after initial treatment (if Touch-up treatment occurred)), and satisfaction with the treatment 4, 24 and 36 weeks after the initial treatment. The safety was evaluated based on occurrence of adverse events, which were collected throughout the investigation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Princess FILLER Lidocaine | Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary. |
Timeline
- Start date
- 2017-09-20
- Primary completion
- 2018-11-19
- Completion
- 2018-11-19
- First posted
- 2018-08-02
- Last updated
- 2025-03-18
- Results posted
- 2025-03-18
Locations
2 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT03611491. Inclusion in this directory is not an endorsement.